Skip to main content

Table 3 Multivariable Cox regression analysis of KLK12 mRNA expression in relation to patients’ outcome in triple-negative breast cancer

From: Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative breast cancer patients

Clinical parametersOSDFS
No.aHR (95% CI)bpNo.aHR (95% CI)bp
Age  <  0.001  <  0.001
 ≤ 60 years601 601 
 > 60 years543.77 (1.93–7.37) 523.16 (1.72–5.80) 
Lymph node status  0.036  0.065
 N0621 611 
 N1/N2/N3521.96 (1.05–3.68) 511.73 (0.97–3.11) 
Tumor size  0.241  0.402
 ≤ 20 mm311 311 
 > 20 mm831.64 (0.72–3.73) 811.35 (0.67–2.74) 
Histological grade  0.465  0.255
 II201 201 
 III941.36 (0.60–3.10) 921.60 (0.71–3.62) 
KLK12 mRNAc  0.066  0.006
 Negative601 581 
 Positive541.80 (0.96–3.38) 542.33 (1.28–4.24) 
  1. The biological marker KLK12 mRNA was added to the base model of clinical parameters: age, residual tumor mass, and ascites fluid volume. Significant p-values (p ≤ 0.05) are indicated in bold
  2. a Number of patients
  3. bHR Hazard ratio (CI Confidence interval) of multivariable Cox regression analysis;
  4. c Dichotomized into positive and negative expression